Inactive Instrument

News Kuros Biosciences AG Swiss Exchange

Equities

CH0011025217

End-of-day quote Swiss Exchange Other stock markets
- ^CHF	-

Apr. 24	Kuros Biosciences Posts Higher Q1 Product Sales	MT
Apr. 17	Kuros Biosciences AG Approves Board of Director and Committee Changes	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kuros Biosciences Posts Higher Q1 Product Sales	Apr. 24	MT
Kuros reports Corporate Highlights as of Q1 2024 including increase in direct MagnetOsTM sales	Apr. 24	EQ
Kuros Biosciences AG Approves Board of Director and Committee Changes	Apr. 17	CI
Annual General Meeting of Kuros Biosciences approves all resolutions	Apr. 17	EQ
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up	Mar. 13	MT
Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023	Mar. 13	EQ
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11	CI
Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update	Mar. 08	EQ
Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference	Feb. 01	EQ
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use	Jan. 31	MT
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand	Jan. 31	CI
Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand	Jan. 31	EQ
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04	CI
Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA	Jan. 04	EQ
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	Dec. 27	EQ
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA	Dec. 27	CI
US FDA Approves Kuros Biosciences' Fibrillar Collagen Matrix Bone Graft Substitute for Interbody Applications	Nov. 29	MT
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages	Nov. 28	CI
Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages	Nov. 28	EQ
Kuros Biosciences Appoints CEO Amid Executive Management Shake-up	23-10-12	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kuros Biosciences AG Swiss Exchange

Equities

CH0011025217

Summary

Filters